This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Stereotaxis Reports First Quarter 2013 Financial Results

Operating loss in the first quarter was $(3.6) million, a 14% reduction compared to $(4.2) million in the prior year quarter. Interest expense increased $0.5 million from the prior year quarter, primarily due to the non-cash amortization of the convertible debt discount.

The net loss for the first quarter was $(4.9) million, or $(0.61) per share, compared to a net loss of $(5.8) million, or $(1.06) per share, reported for the first quarter 2012. The weighted average shares outstanding for the first quarters of 2013 and 2012 totaled 8.0 million and 5.5 million, respectively. Excluding mark-to-market warrant revaluation and amortization of convertible debt discount related to the $18.5 million financing in May 2012, the net loss would have been $(5.0) million, or $(0.63) per share.  

Cash burn for the first quarter of 2013 was $1.1 million, compared to $4.3 million for the first quarter of 2012.

At March 31, 2013, Stereotaxis had cash and cash equivalents of $9.6 million, compared to $7.8 million at December 31, 2012. At quarter end, total debt was $32.5 million, including $18.6 million related to HealthCare Royalty Partners debt. On March 29, 2013, the Company secured an extension of its revolving line of credit with Silicon Valley Bank through June 30, 2013.

Strategic and Financing Alternatives

The Company continues to explore strategic and financing alternatives through discussions with multiple entities and hopes to report more on these activities in the near future. 

Clinical Update

The Company has completed 45% of patient enrollment for the clinical trial of the Vdrive V-Loop™ circular catheter manipulator. The study is a critical step in obtaining clearance of the V-Loop device by the U.S. Food and Drug Administration (FDA). In response to additional FDA requirements for clearance of the V-Sono™ ICE catheter manipulator, the Company completed an enhanced pre-clinical trial and submitted its findings on May 6. Final FDA 510(k) review is underway. Additionally, the Company is launching its first-ever prospective, multi-center atrial fibrillation study in European sites during 2013 and has selected four sites for the study.

2013 Objectives

Stereotaxis does not provide revenue and earnings per share guidance, but provides the following goals for the full year 2013: 
  • Expand global footprint through Japanese approval of Niobe technology
  • Manage operating expenses at current level
  • Strengthen balance sheet through strategic and financing alternatives

Conference Call and Webcast

Stereotaxis will host a conference call and webcast today, May 13, 2013, at 4:30 p.m. Eastern Time, to discuss first quarter results. The dial-in number for the conference call is 1-877-941-4775 for domestic participants and 1-480-629-9761 for international participants. Participants are asked to call the above numbers 5-10 minutes prior to the start time. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at .

About Stereotaxis

Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. With over 100 patents for use in a hospital's interventional surgical suite, Stereotaxis helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced collaboration of life-saving information. Stereotaxis' core Epoch™ Solution includes the Niobe ® ES Remote Magnetic Navigation system, the Odyssey ® portfolio of lab optimization, networking and patient information management systems and the Vdrive Robotic Mechanical Navigation system and consumables. 

The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. The V-Loop circular catheter manipulator is currently in clinical trials in order to obtain clearance by the U.S. Food and Drug Administration; the Company also is pursuing U.S. clearance for the V-Sono™ ICE catheter manipulator. For more information, please visit .

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, our continued access to capital and financial resources, on a timely basis and on terms that are acceptable, our continued listing on the Nasdaq Global Market, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, the outcome of various shareholder litigation filed against us, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.
  March 31,  2013 December 31,  2012
Current assets:    
Cash and cash equivalents  $ 9,560,130  $ 7,777,718
Accounts receivable, net of allowance of $634,813 and $640,183 in 2013 and 2012, respectively  9,842,360  11,551,651
Current portion of long-term receivables  19,067  18,838
Inventories  5,487,887  5,098,241
Prepaid expenses and other current assets  3,475,578  3,492,067
Total current assets  28,385,022  27,938,515
Property and equipment, net  1,878,753  2,141,923
Intangible assets, net  1,904,361  1,979,320
Long-term receivables  18,906  73,199
Other assets  34,158  32,987
Total assets  $ 32,221,200  $ 32,165,944
Liabilities and stockholders' equity (deficit)    
Current liabilities:    
Current maturities of long-term debt  $ 12,317,760  $ 12,264,490
Accounts payable  4,737,918  3,556,688
Accrued liabilities  5,038,255  5,361,810
Deferred contract revenue  9,943,607  9,502,939
Warrants  2,364,271  2,968,348
Total current liabilities  34,401,811  33,654,275
Long-term debt, less current maturities  20,175,614  16,824,736
Long-term deferred contract revenue  359,606  477,159
Other liabilities  --   -- 
Stockholders' equity (deficit):    
Preferred stock, par value $0.001; 10,000,000 shares authorized, none outstanding at 2013 and 2012  --   -- 
Common stock, par value $0.001; 300,000,000 shares authorized, 8,145,930 and 8,018,615 shares issued at 2013 and 2012, respectively  8,146  8,019
Additional paid-in capital  367,048,042  366,053,627
Treasury stock, 4,015 shares at 2013 and 2012  (205,999)  (205,999)
Accumulated deficit  (389,566,020)  (384,645,873)
Total stockholders' equity (deficit)  (22,715,831)  (18,790,226)
Total liabilities and stockholders' equity (deficit)  $ 32,221,200  $ 32,165,944
  Three Months Ended March 31,
  2013 2012
System  $ 2,228,077  $ 5,179,505
Disposables, service and accessories  6,180,127  7,103,723
Total revenue  8,408,204  12,283,228
Cost of revenue    
System  1,191,352  2,342,410
Disposables, service and accessories  1,001,293  1,419,421
Total cost of revenue  2,192,645  3,761,831
Gross margin  6,215,559  8,521,397
Operating expenses:    
Research and development  1,529,207  2,825,207
Sales and marketing  4,856,014  5,998,739
General and administration  3,423,741  3,872,873
Total operating expenses  9,808,962  12,696,819
Operating loss  (3,593,403)  (4,175,422)
Other income (expense)  606,102  (188,070)
Interest income  1,412  1,363
Interest expense  (1,934,258)  (1,450,783)
Net loss  $ (4,920,147)  $ (5,812,912)
Net loss per common share:    
Basic  $ (0.61)  $ (1.06)
Diluted  $ (0.61)  $ (1.06)
Weighted average shares used in computing net loss per common share:    
Basic   8,015,226  5,499,316
Diluted   8,015,226  5,499,316
CONTACT: Company Contact:
         Marty Stammer
         Chief Financial Officer
         Investor Contact:
         Todd Kehrli / Jim Byers
         MKR Group, Inc.

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs